As a model to examine the  α-syn-lowering efficacy of these agents, we assessed the cellular therapeutic impact of these screened SNCA 5′UTR-directed translation blockers to reduce  α-synuclein expression in neural cells lines and subsequently also in the primary neurons from the PAC/Tg(SNCA) genomic human SNCA mouse model of PD (Figures 2 and 6) [48]. This evidence concerns the gene SNCA and Parkinson disease.